Survival of patients with lung cancer treated with vincristine and actinomycin D: An unsuccessful trial

Cancer. 1976 Apr;37(4):1669-72. doi: 10.1002/1097-0142(197604)37:4<1669::aid-cncr2820370409>3.0.co;2-n.

Abstract

Twenty-five patients with lung cancer were treated with actinomycin-D and vincristine (V-D) with only one objective response (IMD). The survival of these patients was compared retrospectively to a group of 49 consecutive patients treated with radiotherapy only during the same time period. Median survival times for the V-D group and radiotherapy controls were 6.5 and 7.5 months, respectively. It is concluded that V-D did not increase survival in patients with lung cancer and should be dropped from the chemotherapeutic armamentarium in lung cancer.

Publication types

  • Comparative Study

MeSH terms

  • Dactinomycin / therapeutic use*
  • Drug Evaluation
  • Drug Therapy, Combination
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / mortality
  • Lung Neoplasms / radiotherapy
  • Male
  • Middle Aged
  • Vincristine / therapeutic use*

Substances

  • Dactinomycin
  • Vincristine